There is an urgent necessity to devise efficient tactics to tackle the inevitable development of resistance to osimertinib, which is a third‐generation epidermal growth factor receptor (EGFR) inhibitor used in treating EGFR‐mutant nonsmall cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is lung cancer.